The clinical efficacy of ICI treatment in NSCLC with B-Raf Proto-Oncogene (BRAF) mutation appears similar to that in unselected NSCLC, indicating that patients with BRAF-mutant NSCLC benefit more from ICI therapy than patients with NSCLC harboring an EGFR mutation or ALK fusion [85]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.